tradingkey.logo

Maravai LifeSciences Holdings Inc

MRVI
3.270USD
-0.030-0.91%
Close 12/26, 16:00ETQuotes delayed by 15 min
473.23MMarket Cap
LossP/E TTM

Maravai LifeSciences Holdings Inc

3.270
-0.030-0.91%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Maravai LifeSciences Holdings Inc

Currency: USD Updated: 2025-12-26

Key Insights

Maravai LifeSciences Holdings Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 115/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.86.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Maravai LifeSciences Holdings Inc's Score

Industry at a Glance

Industry Ranking
115 / 404
Overall Ranking
232 / 4563
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 11 analysts
Buy
Current Rating
3.857
Target Price
+6.85%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Maravai LifeSciences Holdings Inc Highlights

StrengthsRisks
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Fairly Valued
The company’s latest PE is -3.90, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 128.65M shares, decreasing 25.67% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 43.80K shares of this stock.

Financial Health

Currency: USD Updated: 2025-12-26

The current financial score of Maravai LifeSciences Holdings Inc is 7.24, ranking 144/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 41.63M, representing a year-over-year decrease of 36.15%, while its net profit experienced a year-over-year decrease of 74.20%.

Score

Industry at a Glance

Previous score
7.24
Change
0

Financials

6.90

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

6.94

Operational Efficiency

10.00

Growth Potential

5.18

Shareholder Returns

7.19

Maravai LifeSciences Holdings Inc's Company Valuation

Currency: USD Updated: 2025-12-26

The current valuation score of Maravai LifeSciences Holdings Inc is 7.48, ranking 121/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.90, which is -1457.17% below the recent high of 52.87 and -193.13% above the recent low of -11.42.

Score

Industry at a Glance

Previous score
7.48
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 115/404
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-26

The current earnings forecast score of Maravai LifeSciences Holdings Inc is 7.27, ranking 306/404 in the Biotechnology & Medical Research industry. The average price target for Maravai LifeSciences Holdings Inc is 4.00, with a high of 5.00 and a low of 2.00.

Score

Industry at a Glance

Previous score
7.27
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts
Buy
Current Rating
3.857
Target Price
+6.85%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Maravai LifeSciences Holdings Inc
MRVI
11
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-26

The current price momentum score of Maravai LifeSciences Holdings Inc is 4.96, ranking 347/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.75 and the support level at 3.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
4.86
Change
0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.111
Neutral
RSI(14)
41.852
Neutral
STOCH(KDJ)(9,3,3)
11.205
Oversold
ATR(14)
0.183
Low Volatility
CCI(14)
-144.804
Sell
Williams %R
91.275
Oversold
TRIX(12,20)
0.002
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
3.358
Sell
MA10
3.463
Sell
MA20
3.536
Sell
MA50
3.405
Sell
MA100
3.051
Buy
MA200
2.652
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-26

The current institutional shareholding score of Maravai LifeSciences Holdings Inc is 7.00, ranking 85/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 88.93%, representing a quarter-over-quarter decrease of 11.26%. The largest institutional shareholder is The Vanguard, holding a total of 7.13M shares, representing 4.91% of shares outstanding, with 39.20% decrease in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
GTCR Golder Rauner, LLC
20.15M
--
12 West Capital Management, L.P.
12.52M
--
Hudson View Capital LLC
6.87M
--
Braidwell LP
8.35M
--
BlackRock Institutional Trust Company, N.A.
8.41M
+0.63%
The Vanguard Group, Inc.
Star Investors
9.38M
-19.38%
T. Rowe Price Investment Management, Inc.
2.64M
--
Mackenzie Investments
6.07M
-0.72%
Renaissance Technologies LLC
Star Investors
4.19M
+1.84%
Mirabella Financial Services LLP
3.75M
+0.27%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-26

The current risk assessment score of Maravai LifeSciences Holdings Inc is 4.34, ranking 99/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.34
Change
0
Beta vs S&P 500 index
0.33
VaR
+6.25%
240-Day Maximum Drawdown
+69.45%
240-Day Volatility
+83.35%

Return

Best Daily Return
60 days
+12.00%
120 days
+30.58%
5 years
+63.60%
Worst Daily Return
60 days
-8.24%
120 days
-13.03%
5 years
-35.27%
Sharpe Ratio
60 days
+1.12
120 days
+0.97
5 years
-0.32

Risk Assessment

Maximum Drawdown
240 days
+69.45%
3 years
+89.56%
5 years
+97.16%
Return-to-Drawdown Ratio
240 days
-0.49
3 years
-0.29
5 years
-0.19
Skewness
240 days
+0.83
3 years
+2.10
5 years
+1.64

Volatility

Realised Volatility
240 days
+83.35%
5 years
+76.09%
Standardised True Range
240 days
+6.43%
5 years
+29.86%
Downside Risk-Adjusted Return
120 days
+213.74%
240 days
+213.74%
Maximum Daily Upside Volatility
60 days
+52.44%
Maximum Daily Downside Volatility
60 days
+44.25%

Liquidity

Average Turnover Rate
60 days
+1.14%
120 days
+1.43%
5 years
--
Turnover Deviation
20 days
-40.02%
60 days
-31.53%
120 days
-13.97%

Peer Comparison

Biotechnology & Medical Research
Maravai LifeSciences Holdings Inc
Maravai LifeSciences Holdings Inc
MRVI
6.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
Dynavax Technologies Corp
DVAX
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
Charles River Laboratories International Inc
CRL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Maravai LifeSciences Holdings Inc?

The TradingKey Stock Score provides a comprehensive assessment of Maravai LifeSciences Holdings Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Maravai LifeSciences Holdings Inc’s performance and outlook.

How do we generate the financial health score of Maravai LifeSciences Holdings Inc?

To generate the financial health score of Maravai LifeSciences Holdings Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Maravai LifeSciences Holdings Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Maravai LifeSciences Holdings Inc.

How do we generate the company valuation score of Maravai LifeSciences Holdings Inc?

To generate the company valuation score of Maravai LifeSciences Holdings Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Maravai LifeSciences Holdings Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Maravai LifeSciences Holdings Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Maravai LifeSciences Holdings Inc.

How do we generate the earnings forecast score of Maravai LifeSciences Holdings Inc?

To calculate the earnings forecast score of Maravai LifeSciences Holdings Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Maravai LifeSciences Holdings Inc’s future.

How do we generate the price momentum score of Maravai LifeSciences Holdings Inc?

When generating the price momentum score for Maravai LifeSciences Holdings Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Maravai LifeSciences Holdings Inc’s prices. A higher score indicates a more stable short-term price trend for Maravai LifeSciences Holdings Inc.

How do we generate the institutional confidence score of Maravai LifeSciences Holdings Inc?

To generate the institutional confidence score of Maravai LifeSciences Holdings Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Maravai LifeSciences Holdings Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Maravai LifeSciences Holdings Inc.

How do we generate the risk management score of Maravai LifeSciences Holdings Inc?

To assess the risk management score of Maravai LifeSciences Holdings Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Maravai LifeSciences Holdings Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Maravai LifeSciences Holdings Inc.
KeyAI